ReviewJournal of market access & health policy2014
Health technology assessment in middle-income countries: recommendations for a balanced assessment system.
Review in Journal of market access & health policy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study.PharmacoEconomics · 2023Article
- Talent cultivation in health technology assessment: an expert survey.BMC medical education · 2022Article
- Health Technology Assessment in High, Middle, and Low-income Countries: New Systematic and Interdisciplinary Approach For Sound Informed-policy Making: Research Protocole.Risk management and healthcare policy · 2021Article
- Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff.PharmacoEconomics · 2020Article
- Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.PharmacoEconomics - open · 2020Review
- Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status.Frontiers in pharmacology · 2020Article
- How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia.Frontiers in pharmacology · 2019Article
- Balanced assessment systems revisited.Journal of market access & health policy · 2017Article
- Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2016Article
- Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe.Croatian medical journal · 2016Article
- Administrative Process and Criteria Ranking for Drug Entering Health Insurance List in Iran-TOPSIS-Based Consensus Model.Iranian journal of pharmaceutical research : IJPR · 2016Article
- REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE.International journal of technology assessment in health care · 2015Review
- Health technology assessment in the Balkans: opportunities for a balanced drug assessment system.Biotechnology, biotechnological equipment · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of significant differences in institutional contexts, health technology assessment (HTA) systems that are in place in core pharmaceutical markets may not be suitable, fully or in part, for middle-income countries (MICs) and for other noncore markets. Particular challenges may arise when systems based on the economic evaluation paradigm are conceptualized and implemented in MICs, sometimes with an insufficient level of awareness of the local institutional factors that influence pricing and reimbursement decision making. Focusing on pharmaceuticals, this article investigates possible development directions for HTA systems in MICs and noncore markets bearing similar institutional characteristics, and it provides recommendations for a balanced assessment system (BAS). For this, the main paradigms of HTA have also been reviewed briefly and factors influencing HTA and pricing and reimbursement decisions in MICs and in similar noncore countries have been summarized. The proposed BAS framework takes into account available resources and capabilities and is supposed to facilitate access to new pharmaceuticals while ensuring the transparency of decision-making processes and the stability of the pharmaceutical budget.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.